These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 28327188)
41. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Mikuls TR; Farrar JT; Bilker WB; Fernandes S; Saag KG Rheumatology (Oxford); 2005 Aug; 44(8):1038-42. PubMed ID: 15870145 [TBL] [Abstract][Full Text] [Related]
42. Sleep Apnea and the Risk of Incident Gout: A Population-Based, Body Mass Index-Matched Cohort Study. Zhang Y; Peloquin CE; Dubreuil M; Roddy E; Lu N; Neogi T; Choi HK Arthritis Rheumatol; 2015 Dec; 67(12):3298-302. PubMed ID: 26477891 [TBL] [Abstract][Full Text] [Related]
43. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249 [TBL] [Abstract][Full Text] [Related]
44. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562 [TBL] [Abstract][Full Text] [Related]
45. Gout after living kidney donation: a matched cohort study. Lam NN; McArthur E; Kim SJ; Prasad GV; Lentine KL; Reese PP; Kasiske BL; Lok CE; Feldman LS; Garg AX; ; Am J Kidney Dis; 2015 Jun; 65(6):925-32. PubMed ID: 25818677 [TBL] [Abstract][Full Text] [Related]
46. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260 [TBL] [Abstract][Full Text] [Related]
47. Risk of incident atrial fibrillation in gout: a cohort study. Kim SC; Liu J; Solomon DH Ann Rheum Dis; 2016 Aug; 75(8):1473-8. PubMed ID: 26324846 [TBL] [Abstract][Full Text] [Related]
48. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Kim SC; Newcomb C; Margolis D; Roy J; Hennessy S Arthritis Care Res (Hoboken); 2013 Apr; 65(4):578-84. PubMed ID: 22899369 [TBL] [Abstract][Full Text] [Related]
49. Gout, allopurinol use, and heart failure outcomes. Thanassoulis G; Brophy JM; Richard H; Pilote L Arch Intern Med; 2010 Aug; 170(15):1358-64. PubMed ID: 20696962 [TBL] [Abstract][Full Text] [Related]
50. Biologic targets of prescription medications and risk of neurodegenerative disease in United States Medicare beneficiaries. Song Y; Racette BA; Camacho-Soto A; Searles Nielsen S PLoS One; 2023; 18(5):e0285011. PubMed ID: 37195983 [TBL] [Abstract][Full Text] [Related]
51. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479 [TBL] [Abstract][Full Text] [Related]
52. Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study. Landgren AJ; Jacobsson LTH; Lindström U; Sandström TZS; Drivelegka P; Björkman L; Fjellstedt E; Dehlin M Arthritis Res Ther; 2017 Jul; 19(1):173. PubMed ID: 28738835 [TBL] [Abstract][Full Text] [Related]
53. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033 [TBL] [Abstract][Full Text] [Related]
54. Impact of allopurinol on risk of myocardial infarction. Grimaldi-Bensouda L; Alpérovitch A; Aubrun E; Danchin N; Rossignol M; Abenhaim L; Richette P; Ann Rheum Dis; 2015 May; 74(5):836-42. PubMed ID: 24395556 [TBL] [Abstract][Full Text] [Related]
55. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. Hill EM; Sky K; Sit M; Collamer A; Higgs J J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090 [TBL] [Abstract][Full Text] [Related]
56. Poorly controlled gout: who is doing poorly? Chia FL Singapore Med J; 2016 Aug; 57(8):412-4. PubMed ID: 27549096 [TBL] [Abstract][Full Text] [Related]
57. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Lu N; Dubreuil M; Zhang Y; Neogi T; Rai SK; Ascherio A; Hernán MA; Choi HK Ann Rheum Dis; 2016 Mar; 75(3):547-51. PubMed ID: 25739830 [TBL] [Abstract][Full Text] [Related]
58. The association of allopurinol with persistent physical disability and frailty in a large community based older cohort. Zhou Z; Ryan J; Nelson MR; Woods RL; Orchard SG; Zhu C; Gilmartin-Thomas JFM; Fravel MA; Owen AJ; Murray AM; Espinoza SE; Ernst ME J Am Geriatr Soc; 2023 Sep; 71(9):2798-2809. PubMed ID: 37158186 [TBL] [Abstract][Full Text] [Related]
59. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. Cutolo M; Cimmino MA; Perez-Ruiz F Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079 [TBL] [Abstract][Full Text] [Related]
60. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]